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Abstract 
Background: blaVIM-2 harboring Pseudomonas aeruginosa has been reported worldwide and considered as the 
most prevalent metallo-β-lactamase after NDM which are found horizontally transferable and mostly associated with 
integron gene cassettes. The present study investigates the genetic background, transmission dynamics as well as 
stability of blaVIM-2 in clinical isolates of P. aeruginosa harbor blaNDM-1 as well which were collected from October 2012 
to September 2013.
Methods: Two P. aeruginosa strains harboring blaVIM-2 along with blaNDM-1 were isolated from Silchar Medical College 
and Hospital, India. Genetic environment of these resistance determinants was determined and transferability was 
checked by transformation and conjugation assay which was further confirmed by Southern hybridization. Replicon 
typing was performed to determine the incompatibility group of the resistant plasmid and their stability was checked 
by serial passage method. Antimicrobial susceptibility pattern of the isolates was determined and their clonal related-
ness was checked by pulsed field gel electrophoresis.
Results: blaVIM-2 was found to be horizontally transferable through an Inc F type plasmid of approximately 30 kb 
in size. blaVIM-2 was found to be associated with integron gene cassette and was flanked by two different types of 
cassette arrays. Both the isolates were co-harboring blaNDM-1 which was carried within Inc N type of plasmid with an 
approximate 24 kb in size and associated with ISAba125 in their upstream region. Reduced susceptibility rate as well 
as high MIC range was observed in case of wild strains and transformants carrying blaVIM-2 and blaNDM-1.
Conclusions: The detection of this co-existence of multiple carbapenem resistance genes in this part of world is 
worrisome and further investigation is required in order to trace the source and to initiate proper treatment option.
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Background
Carbapenems are considered as the last drug of choice 
for most of the serious infections caused by Gram nega-
tive bacteria, but due to the prevalence of multidrug 
resistant organisms these lifesaving drugs were compro-
mised in treating the patients with severe illness. Gram 
negative bacteria have been documented as the most 
serious threat in the management of acute infections, 
as of exhibiting resistance to antibiotics due to the pro-
duction of carbapenemase enzyme especially metallo-β-
lactamase [1, 2]. Pseudomonas aeruginosa is one of the 
most common nosocomial pathogen causing acute infec-
tions and frequently reported for carbapenem resistance. 
VIM metallo-β-lactamase, the second most predominant 
MBL type responsible for antimicrobial resistance, is 
pandemic and becoming a health hazard. Among the 37 
variant of VIM enzymes, blaVIM-2 has now been spread 
as prevalent MBL among P. aeruginosa in all European 
countries [3] whereas blaNDM-1 and blaVIM-18 has known 
to be originated from India [4, 5] where irrational use of 
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antibiotic is a major contributor for their emergence [6]. 
VIM and NDM type of MBLs are horizontally transfer-
able and found to be associated with mobile genetic ele-
ments, however few molecular information and genetic 
context is available from this part of India. The potential 
for quick and extensive dissemination rate of these resist-
ance genes make over a great concern. The present study 
describes genetic background, transmission dynamics as 
well as stability of blaVIM-2 and blaNDM-1 in clinical iso-
lates of P. aeruginosa.
Methods
Bacterial collection
From October 2012 to September 2013, a total of seven-
teen P. aeruginosa with reduced susceptibility to at least 
a single carbapenem were collected from Silchar Medi-
cal College and Hospital, Silchar. The isolates were then 
identified by standard biochemical reactions, cytochrome 
oxidase activity, citrate utilization, pigment production 
and growth on Cetrimide agar [7].
Characterization of carbapenemases
For detection of carbapenemase production, isolates were 
subjected to modified Hodge test (MHT) and imipenem-
EDTA disc test for metallo-β-lactamase production [4]. 
MHT uses Escherichia coli ATCC 25922 as an indicator 
organism. The presence of clover leaf like indentation in 
MHT was interpreted as a positive result for carbapenem 
hydrolysis.
Molecular characterization of blaVIM and blaNDM gene
PCR assay was performed for detection of blaVIM as 
described earlier [8] as well as other metallo-β-lactamase 
gene (blaNDM, blaIMP, blaGIM, blaSIM, blaSMB) [4] and 
amplified products were further sequenced to confirm 
the presence of resistant gene.
Detection of co‑existing of ESBL genes
Co-existence of ESBL genes were determined by mul-
tiplex PCR targeting blaTEM, blaPER, blaOXA-2, blaSHV, 
blaCTX-M, blaVEB and blaGES [9]. Reactions were per-
formed under the following conditions: initial denatura-
tion at 94 °C for 5 min, 33 cycles of 94 °C for 35 s, 51 °C 
for 1 min, 72 °C for 1 min and final extension at 72 °C for 
7 min. The amplified products were further sequenced to 
confirm the co-existence of ESBL genes.
Detection of genetic context of blaVIM‑2
Genetic environment of blaVIM-2 was determined by per-
forming integrase gene PCR [10] for characterizing the 
class 1 and class 2 integron. The conserved sequences 
5′CS and 3′CS flanking the blaVIM were determined 
using two sets of primers 5′CS and the reverse primer of 
blaVIM, 3′CS and forward primer of blaVIM as described 
earlier [10]. Amplified products were sequenced to 
determine genetic map of blaVIM-2. The reaction con-
dition was: initial denaturation at 95  °C for 3  min, 34 
cycles at 95 °C for 30 s, 46 °C for 1 min, 72 °C for 3 min 
and final extension at 72  °C for 7  min. The presence of 
mobile element like ISCR in each strain was deter-
mined by performing PCR using primers ISCR F (5′- 
RNSBATAGGAADWWNAAHMNV-3′) and ISCR R 
(5′-BNKDTTNWWHTTCCTATVSNY-3′).
Determination of genetic environment of blaNDM‑1
Integron carriage was assessed by performing integrase 
gene PCR for characterizing the class 1 and class 2 inte-
gron. PCR reaction conditions followed was described as 
earlier [10]. The flanking region of blaNDM were deter-
mined using two sets of primers 5CS and the reverse 
primer of blaNDM, 3CS and forward primer of blaNDM 
[10]. The linkage of blaNDM-1 with insertion sequence 
ISAba125 was determined by using forward primer of 
ISAba125 (5′GAA ACT GTC GCA CCT CAT GTT 
TG-3′) and reverse of blaNDM-1 (5′-GTA GTG CTC AGT 
GTC GGC AT-3′) [11].
Plasmid analysis, transformation and conjugation assay
blaVIM positive bacterial isolates were cultured in Luria–
Bertani broth (Hi-Media, India) containing 0.25  μg/ml 
of imipenem. After overnight incubation, plasmids were 
extracted by using QIAprep Spin Miniprep Kit (Qia-
gen, Germany). Isolated plasmids were transformed into 
recipient strain Escherichia coli JM107 by heat shock 
method and transformants were selected on LB agar 
with 0.25μg/ml of imipenem. Conjugation experiment 
was carried out using blaVIM-2 and blaNDM-1 harboring 
transformants as donors and a streptomycin resistant 
E. coli recipient strain B (Genei, India), both the donor 
and reciepient cells were cultured in Luria–Bertani Broth 
(Hi-Media, India) till it reach an O.D. of 0.8–0.9 at A600. 
Cells were mixed at 1:5 donor-to-recipient ratios and 
transconjugants were selected on imipenem (0.25 μg/ml) 
and streptomycin (400  μg/ml) agar plates. Additionally 
conjugation experiment was also tried using P. aerugi-
nosa harboring blaNDM-1 and blaVIM-2 as donor and E. coli 
strain B as recipient.
Southern hybridization for detection of transferability
Southern blotting was performed on agarose gel by in-
gel hybridization with the blaVIM-2 and blaNDM-1 probe 
labelled with DIG HIGH PRIME LABELING MIX 
(Roche, Germany) detection Kit. The digoxigenin-labeled 
blaVIM-2 and blaNDM-1 specific probe was prepared using 
primers VIM-F, VIM-R, NDM-F and NDM-R. Plas-
mid DNA from transformants and transconjugants was 
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separated by PFGE (CHEF DR-III System, Bio-Rad; USA) 
and transferred to nylon membrane (Hybond N, UK) and 
then hybridised with prepared blaVIM and blaNDM spe-
cific probe. Detection was performed by using an NBT 
color detection Kit (Roche, Germany).
PCR based replicon typing
The incompatibility type of the plasmids encoding 
blaVIM-2 and blaNDM-1 were characterized by PCR based 
replicon typing targeting 18 different replicon types such 
as FIA, FIB, FIC, HI1, HI2, I1/Iγ, L/M, N, P, W, T, A/C, K, 
B/O, X, Y, F and FIIA [12].
Antibiotic susceptibility and minimum inhibitory 
concentration (MIC)
Antimicrobial susceptibility of parent strains as well as 
transformants was determined by Kirby-Bauer disc dif-
fusion method against β-lactam and non-β-lactam anti-
biotics (Hi-Media, India). MIC was also determined 
by agar dilution method for the isolates and the trans-
formants carrying PVIM−2 and PNDM−1 towards imipe-
nem (Merck, France), meropenem (AstraZeneca, UK), 
cefepime, aztreonam (Aristo, India), amikacin (Zuche 
pharmaceuticals, India), gentamicin (Pharmakem, India), 
ciprofloxacin(Ranbaxy, India), piperacillin-tazobactam 
(Alkem, India) and polymixin-B (Samarth, India) and 
interpreted as per CLSI guidelines [13].
Stability of blaVIM‑2 and blaNDM‑1
Stability of blaVIM-2 and blaNDM-1 gene was determined 
by serial passage of the isolates as well as of the transfor-
mants in 1:1000 ratios without antibiotic pressure [14]. 
After each passage the test isolates were subjected to 
phenotypic detection of MBL and further confirmed the 
presence of blaVIM and blaNDM by PCR assay.
Pulsed field gel electrophoresis
blaVIM and blaNDM positive isolates were typed by pulsed 
field gel electrophoresis where chromosomal DNA was 
prepared in agarose blocks and digested with restriction 
enzyme Xba1 (Promega, USA). DNA fragments were 
separated with CHEF-DR III apparatus (Bio-Rad, USA) 
and the electrophoresis conditions used were for 24 h at 
6 V/cm with pulse rate of 10–40 s as described previously 
[15]. Clonal relatedness within the isolates was deter-
mined by comparing the band patterns.
Ethical approval
The work was approved by Institutional Ethical commit-
tee of Assam University, Silchar vide Reference Number: 
IEC/AUS/C/2014-001. The authors confirm that partici-
pants provided their written informed consent to partici-
pate in this study.
Results
Two clinical isolates of P. aeruginosa (PA-37 and PA-131) 
harboring blaVIM were recovered from Silchar Medi-
cal College and Hospital, India. The gene was further 
sequenced and confirmed as blaVIM-2 variant. The first 
isolate (PA-37) was recovered from pus samples of a 
55 year old female patient suffering from wound infection 
admitted in surgery ward in December 2012 while the 
second one (PA-131) was isolated from urine of a 40 years 
old female patient with UTI, who attended gynecology 
outpatient department (OPD) in the month of February 
2013. blaVIM-2 was found to be horizontally transferable 
as the gene could be successfully conjugatively trans-
ferred from transformed E. coli JM107 to recipient E. coli 
strain B through an Inc F type plasmid having approxi-
mate size of 30 kb. These findings were further confirmed 
by Southern hybridization results. However, conjuga-
tive transfer of plasmids from P. aeruginosa to E. coli was 
not successful with our experiment. In both the isolates 
blaVIM-2 was located within integron gene cassette and 
was flanked by other antimicrobial resistant determinant 
like gene for aminoglycoside resistance (Fig.  1). The two 
different types of cassette arrays observed were blaVIM-2-
aadB-dhfrA-orfC-qacE-sul1 (PA-37) and aadB-aacA7-
blaVIM-2-dhfrA1-orfC-qacE-sul1 (PA-131). Both the 
isolates were co-harboring blaNDM-1 and further ESBL 
screening revealed the presence of blaVEB-1 gene in these 
isolates. However, blaNDM-1 gene could not be hybridized 
with 30 kb plasmid that was harboring blaVIM-2, but with 
a 24  kb plasmid which was successfully hybridized with 
blaNDM-1 specific probe (Fig. 2). Linkage of ISAba125 was 
observed in the upstream region of blaNDM-1 whereas no 
association with integron gene cassette could be estab-
lished. Interestingly on analyzing the stability of MBL 
genes i.e. blaVIM-2 and blaNDM-1, in case of wild type iso-
lates these resistant genes were stable even after hundred 
consecutive passages but among their transformants, 
complete plasmid was lost after fifty-six passages in case 
of blaVIM-2 while blaNDM-1was retained till ninety passages 
without any antibiotic pressure. These blaVIM-2 positive 
Fig. 1 Genetic Context of blaVIM-2
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isolates showed resistance towards most of the antibiot-
ics including piperacillin/tazobactam, co-trimoxazole, 
amikacin, gentamicin, netilmicin and quinolone group 
of drugs. MIC values obtained for both the isolates were 
above breakpoint towards ciprofloxacin, aminoglycosides, 
β-lactam-β-lactamase inhibitor as well as to polymixin B 
(Table 1). The two blaVIM-2 harboring isolates of P. aerugi-
nosa were found to be clonally different from each other 
on the basis of their PFGE banding pattern (Fig. 2).  
Discussion
It has been evidenced that the rapid emergence and dis-
semination of carbapenemase producing bacteria in this 
subcontinent is mainly due to the acquisition of blaNDM 
[4]. But in the present study, we described an addi-
tional carbapenem resistance determinant i.e. blaVIM-2 
which played a significant role in carbapenem resist-
ance. Although blaVIM-2 with integron gene cassette 
is reported in previous studies [8], while in the present 
study, the genetic context of blaVIM-2 underscores their 
diverse origin and persistence along with other resist-
ant genes. In the present study blaVIM-2 was found to be 
associated with the gene cassette along with other resist-
ance determinants which is in agreement to the reports 
of Toleman et  al. [16]. The association of other resist-
ance determinants along with VIM type MBL confers the 
phenotype to become resistant to most of the available 
antimicrobial agents. The study reports the presence of 
Fig. 2 PFGE and hybridization analysis of blaNDM-1. Lane 1 and 4 The undigested total DNA of PA 37 and PA 131 respectively; Lane 2 and 3 The PA 37 
total DNA is digested with S1 and Xba I respectively; Lane 5 and 6 PA 131 total DNA digested with S1 and Xba I respectively; Lane 7 The undigested 
plasmid of PA 37; Lane 8 and 9 E. coli transconjugant carrying plasmid of PA 37 digested with S1 and Xba I respectively; Lane 10 Hybridized PPA 37 
with probe; Lane 11 The undigested plasmid of PA 131; Lane 12 and 13 E. coli transconjugant carrying plasmid of PA 131 digested with S1 and Xba I 
respectively; Lane 14 Hybridized PPA 131 with probe; Lane 15 The total DNA of recipient E. coli without plasmid; Lane 16 and 17 The total DNA of recipi-
ent E. coli without plasmid digested with S1 and Xba I respectively
Table 1 MIC (μg/ml) of the blaVIM‑2 and blaNDM‑1 harboring isolates and their transformants
a Donor strain
b Recipient E. coli carrying plasmid of blaVIM-2
c Recipient E. coli carrying plasmid of blaNDM-1
Organisms Imipenem Meropenem Cefepime Aztreonam Amikacin Gentamicin Ciprofloxacin Piperacillin‑tazobac‑
tam
Polymixin B
PA-37a >256 >256 >256 >256 >256 >256 256 >256 >256
E. coli JM107
(pVIM−2/37)b
64 32 128 64 128 64 64 64 32
E. coli JM107
(pNDM−1/37)c
64 64 128 64 128 128 64 64 32
PA-131a >256 128 >256 >256 >256 >256 256 >256 256
E. coli JM107
(pVIM−2/131)b
16 16 64 64 64 64 64 64 32
E. coli JM107
(pNDM−1/131)c
32 16 128 64 64 64 64 64 16
E. coli JM107 0.06 0.012 0.06 0.12 0.06 0.125 0.06 0.12 0.006
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aminoglycosides resistance genes aadB and aacA7 on the 
same gene cassette along with blaVIM-2, thus making the 
phenotype resistance to amikacin and gentamicin as well. 
In the year 2012, Toleman et al. [11] reported the asso-
ciation of insertion sequence ISAba125 in the upstream 
region of blaNDM-1 in Acinetobacter baumanii, we too 
observed the same insertion sequence present in the 
upstream region of blaNDM-1 in P. aeruginosa. Presence 
of NDM-1 in P. aeruginosa was for first time recorded 
in 2011 from patients in Serbia [17] and the same work-
ing group has reported that resistance determinant is 
chromosomally located in this particular organism [18]. 
Similarly, a report from India also has established its 
chromosomal location [19]. However, in our recent study 
we found presence of blaNDM-1 on plasmid DNA indi-
cating a possible shift from one to another genetic loca-
tion [20]. Future experiments will show which direction 
(chromosome to plasmid or vice versa) of the transfer 
took place in the organism. High MIC range as well as 
reduced susceptibility rate against majority of the tested 
antibiotics was observed in case of blaVIM-2 and blaNDM-1 
harboring wild strains and transformants of blaVIM-2 
and blaNDM-1. Earlier studies reported [16] that carbap-
enemase producing isolates remain susceptible to poly-
mixin B whereas both of our study isolates were found 
to be resistant to this antibiotic, which could be a chal-
lenging situation with no or too limited treatment option. 
The association of mobile genetic element with blaVIM-2 
may facilitate their mobilization to other susceptible 
organisms. On performing the transmission dynamics of 
the strains and it was evident that blaVIM-2 and blaNDM-1 
was horizontally transferable. It may be noted that in our 
study, the plasmid of P. aeruginosa encoding the NDM-1 
was conjugally transferred from the E. coli transformants 
to recipient E. coli strain although conjugation of the 
same plasmid was not successful from original host P. 
aeruginosa to E. coli. The reason for absence of plasmid 
conjugation could be due to presence of some physiologi-
cal barriers within these two strains or we did not find 
the appropriate laboratory conditions for initiation of 
conjugation or present plasmid do not carry functional 
Tra operon in P. aeruginosa. Serial passage of transfor-
mants harboring both blaVIM-2 and blaNDM-1 showed that 
blaNDM-1 gene is more stable compare to blaVIM-2, may 
be because E. coli is an unnatural host for blaVIM-2. The 
distinguishable pulsotypes of the two strains along with 
their different genetic arrangements indicates horizontal 
acquisition from diverse source and antibiotic pressure in 
this hospital setting.
Conclusions
Co-existence of multiple carbapenem resistance deter-
minants in hospital isolate is worrisome and a matter of 
concern for infection control management considering 
the treatment option and clonal expansion. Thus, the cur-
rent finding is of epidemiological interest, which requires 
immediate steps to initiate proper treatment option.
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